Champions Oncology Interest Expense 2011-2026 | CSBR

Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.

Includes:

Interest on bank loans
Interest on corporate bonds
Interest on leases
Interest on credit lines and overdrafts

High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.

Low interest expenses with high profits are a sign of financial stability.

Annual Interest Expense Champions Oncology

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
73 K	48 K	-11 K	-24 K	71 K	-42 K	-39 K	-89 K	-56 K	-38 K	-170 K	-164 K	-25 K	-15 K	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
73 K	-170 K	-34.4 K

Quarterly Interest Expense Champions Oncology

2025-Q2	2025-Q1	2024-Q3	2024-Q2	2024-Q1	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
75 K	-	7 K	5 K	-	-105 K	14 K	-	-32 K	-9 K	-18 K	-	-8 K	26 K	43 K	-	-14 K	9 K	9 K	64 K	1 K	27 K	27 K	-12 K	-7 K	-7 K	-7 K	1 K	-8 K	-13 K	-13 K	-51 K	-8 K	-16 K	-16 K	-9 K	-6 K	-14 K	-14 K	-10 K	-7 K	-27 K	-27 K	31 K	-10 K	-29 K	-29 K	-1 K	-12 K	-5 K	-6 K	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
75 K	-105 K	-4.59 K

Interest Expense of other stocks in the Biotechnology industry

Issuer	Interest Expense	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	4.66 M	-	2.43 %	$ 254 M	Germany
Adagene ADAG	1.11 M	$ 2.62	28.82 %	$ 147 M	China
Acorda Therapeutics ACOR	31.5 M	-	-24.86 %	$ 820 K	USA
Alterity Therapeutics Limited ATHE	2.28 K	$ 3.51	7.34 %	$ 8.45 B	Australia
AgeX Therapeutics AGE	4.9 M	-	-10.17 %	$ 12.2 K	USA
Aeglea BioTherapeutics AGLE	-20.7 M	-	-	$ 1.01 B	USA
Amphastar Pharmaceuticals AMPH	4.08 M	$ 25.92	-0.86 %	$ 1.26 B	USA
Akero Therapeutics AKRO	4.67 M	-	-	$ 3.67 B	USA
Aravive ARAV	2.84 M	-	-13.39 %	$ 1.45 M	USA
Athira Pharma ATHA	3.96 M	-	-	$ 269 M	USA
Akouos AKUS	-1.72 M	-	0.23 %	$ 488 M	USA
BioLineRx Ltd. BLRX	9.07 M	$ 3.1	4.49 %	$ 908 M	Israel
Applied Molecular Transport AMTI	-4 K	-	-	$ 10.1 M	USA
Ascendis Pharma A/S ASND	65.5 M	$ 235.41	2.95 %	$ 5 B	Danmark
BioXcel Therapeutics BTAI	20.2 M	$ 1.84	1.66 %	$ 4.66 M	USA
ARCA biopharma ABIO	9 K	-	1052.0 %	$ 415 M	USA
Aytu BioScience AYTU	-512 K	$ 2.66	-1.85 %	$ 16.7 M	USA
Arrowhead Pharmaceuticals ARWR	5.26 M	$ 67.49	-3.02 %	$ 9.03 B	USA
Brickell Biotech BBI	5 K	-	-5.38 %	$ 6.06 M	USA
Can-Fite BioPharma Ltd. CANF	227 K	$ 4.51	8.41 %	$ 9.81 B	Israel
BeiGene, Ltd. BGNE	-12.6 M	-	0.49 %	$ 251 B	Cayman-islands
Adaptimmune Therapeutics plc ADAP	-807 K	-	-15.15 %	$ 60.3 M	Britain
AIkido Pharma AIKI	-5.79 M	-	1.93 %	$ 17.4 M	USA
Albireo Pharma ALBO	3.69 M	-	-0.23 %	$ 916 M	USA
Acer Therapeutics ACER	432 K	-	2.71 %	$ 14 M	USA
Bellicum Pharmaceuticals BLCM	2.66 M	-	-9.72 %	$ 5.89 M	USA
Alpine Immune Sciences ALPN	476 K	-	-	$ 2.17 B	USA
AlloVir ALVR	1.19 M	-	4.14 %	$ 49.1 M	USA
Coherus BioSciences CHRS	40.5 M	$ 2.04	28.3 %	$ 192 M	USA
Ampio Pharmaceuticals AMPE	-5.01 K	-	-11.43 %	$ 502 K	USA
Biogen BIIB	250 M	$ 171.89	-1.1 %	$ 25 B	USA
BioVie BIVI	4.3 M	$ 1.2	-3.7 %	$ 1.77 M	USA
Baudax Bio BXRX	1.36 M	-	0.59 %	$ 63 K	USA
Calithera Biosciences CALA	2.65 M	-	-10.95 %	$ 876 K	USA
Arena Pharmaceuticals ARNA	4.16 M	-	-6.81 %	$ 3.04 B	USA